Best Penny Stock Trading – 2019

studio shot of money and penny stock

Penny stocks are very popular amongst small investors who don’t want to spend more than a penny or a dollar on a stock. However, penny stocks are known for their volatility and represent a challenge. Despite being dead cheap, these stocks can offer a significant revenue if they make progress over time. In this article, we’re going to give you the best penny stocks to invest.

  • Best Penny Stock Trading of 2019

vTv Therapeutics (VTVT)

Back in December 2018, VTVT shares surged more than 200 percent, which is an astonishing result. The company then decided to buy 815,000 shares at a price of $1.84 per share. At that time, shares were already around $1 and in May 2019, the price still remains under $3. This price, as they say, served as resistance back in the last quarter of 2018.

Alliqua Biomedial (ALQA)

Alliqua Biomedial is a very popular stock in 2019 and was also popular near the end of 2018. The reason for this is its subsequent 200 percent rally, with shares being down nearly 60 percent from highs. Still, it’s 36 percent up since the M&A news back in 2018, so we can say it’s a pretty good investment in 2019.

Axsome Therapeutics (AXSM)

In 2019, Axsome Therapeutics is one of the most searched stocks. This is because AXSM performed really well in 2018 and in 2019, and now, it’s up about 215 percent. After the company disclosed a Phase 2 trial for the depressive disorder treatment, the stock rallied more than 200 percent. Even though they have 2.8 million share stock offering, their shares are down around 14 percent from recent highs.

Adial Pharma (ADIL)

ADIL was pretty consistent in setting higher lows since it broke the $2 level in November 2018. This trend wasn’t in favor of this stock as it raised to $7.45 at one point in December 2018. Still, in May 2019, we think that ADIL is worth checking, as it’s one of the more popular stocks in 2019.

‘Image Credit: Unsplash’

Disclaimer: The information on this site is provided for discussion purposes only, and should not be misconstrued as investment advice. Under no circumstances does this information represent a recommendation to buy or sell securities.